Multi-Specific Engager Proteins with Diverse & Novel Functionalities
- Our Phase 1/2 clinical program solves critical issues confronting CAR-T cell therapies
- Our clinical development programs illustrate how the modularity inherent in our technology broadens the pipeline to solid tumors and AML
- Our unique costimulatory engagers provide an early look at the future of bispecific and multi-specific therapies